We examined the potential for some of the abnormalities of vascular endothelium found in diabetes mellitus to cause neuropathic changes. Non-diabetic rats were treated for 2 months with the cyclo-oxygenase inhibitor flurbiprofen (5 rag-kg -1-day 1) to reduce prostacyclin production, the nitric oxide synthase inhibitor N°-nitro-I~-arginine (5 or 25 mg. kg -~. day-l), or combined treatment. There were dosedependent reductions in sciatic motor and saphenous sensory conduction velocity. The two inhibitors acted synergistically, thus, the 5-6 % motor conduction deficits (p < 0.01) produced by either flurbiprofen or N<nitro-L-arginine (5 mg. kg -I. day '1) increased to 17 % (p < 0.001) for combined treatment. With N<nitro-L-arginine (25 mg. kg -1. day -~) and flurbiprofen, motor and sensory conduction velocity were reduced by 23 % (p < 0.001) and 12 % (p < 0.001), respectively, matching the deficits following 2-month streptozotocin diabetes. N<nitro-L-arginine (25 mg-kg -~. day -~) and flurbiprofen together produced a 13 % prolongation of the time taken for 80 % hypoxic conduction failure in vitro (p < 0.05) and a i0 % reduction in sciatic capillary density. A second investigation tested an alternative hypothesis that overproduction of nitric oxide was responsible for vascular-related complications in diabetes, the prediction being that N<nitro-L-arginine (5 mg-kg ~1-day -I) would prevent nerve dysfunction. However, rather than prophylaxis during 2-month streptozotocin diabetes, treatment exacerbated nerve abnormalities. Thus, NQnitro-L-arginine worsened (8%, p < 0.001) the motor conduction deficit, there was an 11% increase in hypoxic conduction failure time (p < 0.01) and an 11% reduction in endoneurial capillary density (p < 0.01). We conclude that overproduction of nitric oxide is unlikely to be involved in the aetiology of experimental diabetic neuropathy. However, endothelial dysfunction resulting in impaired nitric oxide and prostacyclin synthesis could make a substantial contribution.
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Vascular factors may contribute to the aetiology of neuropathy in diabetes mellitus, exerting their action via impaired nerve blood flow and endoneurial hypoxia [1] . Evidence favouring this view includes measurement of endoneurial blood flow and oxygen tension in diabetic rats and patients [2] [3] [4] [5] , and parallels with some neurological abnormalities found for central hypoxaemia [6] [7] [8] .
Dysfunction of vessels and vascular beds in diabetic animals and patients is well documented [9, 10] ; a broad range of abnormalities are found affecting both vascular smooth muscle and endothelium. Thus, reactivity to c~-adrenoceptor agonists is altered [11] , voltage-dependent Ca 2+ channel activity is enhanced [12] , angiotensin converting enzyme levels are elevated [9] , and ATP-sensitive K ÷ channel mediated vasodilation is reduced [10, 13] . For endothelium, major factors are diminished synthesis of prostacyclin and nitric oxide (NO) [10, [14] [15] [16] [17] , and increased levels of circulating endothelin [18] . Many of these findings have been made on isolated vascular tissues in vitro, although several are supported by in vivo investigations [16] . However, it is difficult to extrapolate from experiments which suggest generalised abnormalities of smooth muscle or endothelium to the performance of the whole cardiovascular system in conscious animals or to specific effects on vascular beds of organs susceptible to diabetic complications such as peripheral nerve.
The effects of diabetes on regional blood flow in conscious rats are complex. It is notable, though, that hindlimb blood flow is reduced and the effects of agents that modulate NO production are attenuated [19, 20] . Given that prostacyclin synthesis by sciatic nerve epi/perineurial vessels is impaired by diabetes [15] , that deficits in NO-mediated endothelium-dependent relaxation are prevented by aldose reductase inhibition [10] , and that nerve conduction abnormalities are prevented by both aldose reductase inhibitors [21, 22] and evening primrose oil treatment (which supplies substrate for prostacyclin production) [23] [24] [25] , the following hypothesis may be advanced. Endothelial abnormalities in diabetes reduce the synthesis of prostacyclin and NO, which decreases local blood flow and favours platelet aggregation; vascular effects that play a major role in the aetiol0gy of peripheral nerve dysfunction in diabetes. To test the potential for causing nerve conduction abnormalities, non-diabetic rats were chronically treated with the cyclo-oxygenase inhibitor flurbiprofen to reduce prostacyclin synthesis, and the NO synthase inhibitor N~-nitro-L-arginine (NOARG) [26] , both alone and in combination.
Recently, Corbett et al. [27] suggested an hypothesis for vascular dysfunction that is diametrically opposed to the present proposition. Based on the idea that aminoguanidine, which prevents the development of neurological complications in experimental diabetes [28, 29] , inhibited NO synthase, and that a conventional NO inhibitor prevented glucose-induced vascular changes in granulation tissue, it was argued that overproduction of NO occurs in diabetes. The potential resultant vasodilation would chronically increase capillary pressure. This would damage vascular beds in tissues prone to diabetic complications, causing deleterious functional changes. Thus, the hypothesis predicts that chronic NOARG treatment should prevent nerve dysfunction in diabetic rats, whereas the thesis presented above anticipates a worsening of function. These predictions were tested in a second study.
Materials and methods

Animals and treatment
Male Sprague-Dawley rats (Aberdeen University breeding colony), 19 weeks of age at the start of the study were used. For the first investigation, one group of rats was untreated for a further 2 months (agematched control group). Five other groups of rats were given different treatment regimens over 2 months. One group received the cyclo-oxygenase inhibitor flurbiprofen (Sigma, Poole, Dorset, UK) in the drinking water such that the effective dose was approximately 5 mg-kg -1-day-< This dose was chosen as it was previously found to completely block the effects of o)-6 essential fatty acid treatment in vivo for diabetic rats [25] . The dose approximately corresponds to that recommended for the treatment of rheumatoid arthritis in patients and, in animal experiments, substantially blocks cs~clo-oxygenase-mediated prostanoid production in a variety of tissues both in vivo and in vitro [30] . Two other groups were treated with N~-nitro-L-arginine (Sigma) in the drinking water at doses of 5 and 25 mg-kg < -day -~, respectively. Preliminao " experiments on two rats with chronically implanted carotid cannulae (under 2-5 % halothane anaesthesia) were used to establish the oral availability of NOARG. Mean systemic blood pressure was monitored over 2 days prior to the start of NOARG treatment and for 2 days after, using the 5 mg.kg 1,day 1 dose. Rats were conscious and unrestrained, the cannula was connected to a pressure transducer, tubing being guarded by a flexible stainless steel sheath. The average resting blood pressure was 117.5 mm Hg before treatment, and this was increased to 136.3 mm Hg with 5 mg .kg I .day < NOARG. Measurements were not made for the 25 mg. kg -~. day -t dose, partly for technical reasons related to maintaining the patency of the cannulae, but also because of signs of physiological stress in a pilot study where rats were introduced directly to full treatment. Thus, for these ex-perimental animals, treatment was introduced gradually over a 5-day period starting from half the intended dose. Two further groups of rats were given flurbiprofen (5 mg. kg -1. day -I) in combination with NOARG (5 or 25 rag. kg -1. day0; again, for the high NOARG dose, treatment was gradually introduced over 5 days.
For the second investigation, rats were made diabetic with streptozotocin (Sigma) (40 mg-kg -I in 20 mmol-1-1 sodium citrate buffer, pH 4.5, i. p.). Diabetes was verified 24 h later by estimating hyperglycaemia and glycosuria (Visidex II and Diastix; Ames, Slough, Bucks., UK). Final plasma glucose levels were determined using a standard test kit (GOD-Perid method; Boehringer Mannheim, Mannheim, FRG) on samples taken on the day of the experiments. Diabetic rats were divided into two groups; one was untreated for 2 months and acted as a control group, whereas the other group was treated with 5 mg. kg 1. day -~ NOARG for 2 months.
Nerve conduction velocity
In final experiments (1-1.5 g. kg -1 urethane anaesthesia i.p.), nerve conduction velocity (NCV) was measured in vivo between the sciatic notch and the knee for nerve branches supplying tibialis anterior (peroneal division) and gastrocnemius (tfbial division) muscles; an average value for these branches was taken as representative of sciatic motor NCV [3] . Sensory NCV was measured in the saphenous nerve between the groin and ankle. Rectal and nerve temperatures were monitored, and regulated between 36.5 and 37.5 °C. Methods have previously been described in detail [21] .
Sciatic nerve resistance to hypoxia in vitro
The sciatic nerve trunk was removed between the sciatic notch and its bifurcation at the knee. It was mounted on bipolar stimulating (proximal end) and recording electrodes (distal end) in a chamber at 35-36 °C. It contained Krebs' solution with 5.5 mmol. 1-1 glucose for nerves from non-diabetic rats and 40 mmol.1 -I glucose for nerves from diabetic rats. The bathing fluid was gassed with 95 % 02/5 % CO2. Nerves were equilibrated for 30 min, then the chamber was refilled with mineral oil pre-gassed with 100 % Nz. Nerves were stimulated with just supramaximal pulses (1 I~, 0.05 ms width, 10 mA), and compound action potential amplitude was monitored at 2-min intervals until it fell below 10 % of its initial value. Methods have previously been described in detail [23] .
Sciatic nerve capillary density
At the end of the experiment, rats were killed by exsanguination. The sciatic nerve trunk, between the sciatic notch and its bifurcation at the knee, was removed and divided into 5 equal length pieces which were mounted together, along with soleus and tibialis anterior muscle which also acted as support tissue. Samples were frozen in isopentane prechilled in liquid nitrogen. Sections of 10 gm were cut on a cryostat, and capillary endothelium was stained for alkaline phosphatase [31] . Three sections, each 90 gm apart, were taken and all capillaries in all nerve fascicles were counted with the aid of a projection microscope. Fascicle outlines were traced and their areas measured using a digitizing pad linked to a microcomputer. Thus, the measurements represent average capillary density for repeated sampling between sciatic notch and knee, on a fascicular area of approximately 10 mm 2 for each nerve.
Statistical analysis
Results are expressed as group means _+ SEM. Data were subjected to one-way analysis of variance, and any statistically significant differences (p < 0.05) were assigned to individual between group comparisons using the Student's t-test, applying the Bonferroni correc- 
Results
Investigation 1: effects of flurbiprofen and Na-nitro-L-arginine (NOAR G) treatment on nerve function in non-diabetic rats
Plasma glucose levels were in the range 6.9 _+ 0.3 to 8.3 +_ 0.2 retool. 1 -t. Body weight increased in all groups over the 2-month period, from a starting weight in the range 456 _+ 17 g to 499 + 15 g. Weight increases were approximately 13 % in age-matched control, low-dose NOARGtreated (5 mg.kg -~-day -1) and flurbiprofen-treated groups with and without low-dose NOARG treatment.
The two groups treated with high-dose NOARG (25 mg. kg -~. day -I) had a lesser weight gain of around 6 %. Figure 1A and 1B respectively. Flurbiprofen or low-dose NOARG treatment produced small but significant reductions in motor NCV (5.5 %, p < 0.01; 6.0 %, p < 0.001, respectively) compared with the age-matched control value of 67.8 _+ 0.6 m. s -1. However, there was no significant effect on sensory NCV, which was 60.9 +_ 0.3 m. s -1 in agematched controls. High-dose NOARG treatment caused a greater reduction in motor NCV (16.9 %,p < 0.001) and a significant diminution of sensory NCV (9.8 %,p < 0.001) compared with age-matched controls. These effects were also greater than with low-dose NOARG treatment (p < 0.001 for both motor and sensory NCV). Combined treatment with fluxbiprofen and low-dose NOARG caused motor and sensory NCV deficits approximately equivalent to high-dose NOARG treatment alone (17.2 %, motor; 9.3 %, sensory; both p < 0.001 compared NOARG, Na-nitro-L-arginine, "p < 0.001, b p < 0.01 compared to diabetic group. Data are group means ± SEM with the age-matched control group). The lowest values for NCV were found for combined flurbiprofen and highdose NOARG treatment, the deficits being 21.9 % and 11.9% for motor and sensory nerves, respectively (p < 0.001). These were significantly greater than for highdose NOARG alone for motor (p < 0.01) but not for sensory NCV.
Curves illustrating the decline in sciatic nerve compound action potential amplitude with hypoxia duration in vitro for some of the groups are shown in Figure 2A.There were no significant differences between data for age-matched control and flurbiprofen or lowdose NOARO-treated groups (curves not shown). However, low-dose NOARO with flurbiprofen (data not shown) and high-dose NOARO treatments resulted in very similar curves that showed a significantly greater early hyperexcitability phase [32] (p <0.05 from 2 to 10 min for flurbiprofen and low-dose NOARG and from 4 to 10 min for high-dose NOARG). There was also a tendency for these curves to be shifted to the right compared to age-matched controls, which was significant (p < 0.05) from 26 min onward. For the high-dose NOARG and flurbiprofen-treated group, both the hyperexcitability and the shift to the right were enhanced such that all data points from 2 min onward were significantly different (p < 0.05) from the control group.
Figure2B summarizes the durations of hypoxia necessary for 80 % reductions in compound action potential amplitude (Ts0) for all groups. Flurbiprofen and lowdose NOARG, both alone and in combination, had no significant effect on Ts0 compared with the age-matched control group. With high-dose NOARG alone, Ts0 increased by 6.3 % which was not statistically significant but, in combination with flurbiprofen, the increase was 12 % (p < 0.05). Table 1 shows endoneurial capillary density for all groups. Compared to control rats capillarization tended to be decreased in all treatment groups. However, this was only statistically significant (p < 0.05) for the approximately" 10 % reductions found with high-dose NOARG treatment, alone and combined with flurbiprofen.
Investigation 2: effects of N~-nitro-L-arginine (NOARG) treatment on nerve function in streptozotocin-diabetic rats
Diabetes caused a 22.5 9/0 decrease in body weight over 2 months which was unaffected by low-dose NOARG (5 rag-kg -I. day -1) treatment. Plasma glucose concentrations for untreated and treated diabetic groups were 37.9 + 2.6 and 38.9 + 1.6 mmol. 1-1, respectively. Table 2 shows motor and sensory NCV data and endoneurial capillary density. NOARG treatment caused a 7.8% motor NCV reduction (p <0.001), and a 5.1% deficit in sensory NCV that was not statistically significant. NOARG treatment also resulted in an 11.5 % reduction (p < 0.01) in sciatic capillary density compared to the untreated diabetic group. Figure 3 illustrates hypoxic resistance curves for the untreated and NOARG-treated diabetic groups. The latter showed a greater initial hyperexcitability and was also shifted to the right (p < 0.01 for all points from 2 to 42 rain) indicating greater hypoxic resistance. Ta0 (Fig. 3, inset) was 31.1+0.7 rain for untreated diabetes, which was 11.3 % increased by NOARG treatment (p < 0.01). 
Discussion
The data demonstrate that creation of endothelium dysfunction in non-diabetic rats, by pharmacological blockade of local vasodilator production, causes NCV deficits similar to those found in experimental diabetes. A test of the converse notion, that over-production of NO in diabetic rats [27] could account for neuropathic abnormalities, showed that this was highly improbable. Thus, partial inhibition of NO synthesis led to further functional impairment. Flurbiprofen or low-dose NOARG treatments alone caused very modest NCV changes in non-diabetic rats but their combined effects were more than additive, which may be viewed in terms of inhibition of two mutually compensatory mechanisms [33] . Thus, addition of flurbiprofen to low-dose NOARG had similar consequences to a five-fold increase in NOARG. It is plausible that endothelial dysfunction of prostacyclin and NO synthesis contribute synergistically to the aetiology of diabetic neuropathy. Numerous studies have identified reduced endothelium-dependent relaxation in vessels and vascular beds from diabetic animals and patients [10, 15-17, 19, 20, 34, 35] . In aortas from diabetic rats an NO synthesis deficit was prevented by aldose reductase inhibition [10] , which also improves nerve function [21] . Reduced prostacyclin production or sensitivity with diabetes has been noted in several tissues including sciatic vascular supply [14, 15, 36] . There, the abnormality arises from a tack of substrate as sciatic peri/epineurial vessels from diabetic rats synthesised prostacyctin at a greater rate than controls when supplied with arachidonic acid in vitro [15] . Evening primrose oil treatment increases plasma arachidonic acid concentration, which would promote prostacyclin production, and nerve function is improved [23] . The argument for the importance of prostanoid synthesis deficits in neuropathy is supported by the findings that the action of evening primrose oil in diabetic rats is completely blocked by flurbiprofen [25] , and that nerve function is also restored by a prostacyclin analogue [37] .
Whilst treatment with flurbiprofen and high-dose NOARG for 2 months caused NCV deficits similar to those seen with the same duration of untreated diabetes, effects on hypoxic resistance were more modest. Thus, I"80 values (24.6 +_ 0.5 min) resemble those noted in a previous investigation [38] for 1-month diabetes (24.8 + 0.9 min). Hypoxic resistance and NCV deficits in diabetes follow different time courses, the former progressively increases over the first 3 months of diabetes, whereas major changes in the latter occur within the first 2-4 weeks of diabetes [21, 38] . Thus, treatment of non-diabetic rats with flurbiprofen and high-dose NOARG for 2 months was equivalent to t-month diabetes when all measures of nerve function examined are considered. It is, therefore, plausible that endothelium dysfunction could substantially contribute to diabetic neuropathy, although the failure to completely mimic diabetic neuropathic effects also suggests the involvement of other factors. These could include direct effects on nerve metabolism, for example, because of polyol pathway activity [39] [40] [41] or increased glucose availability [42] . However, NCV deficits and resistance to N. E. Cameron et al.: Endothelium and nerve function ischaemia also occur in experimental hypoxic neuropathy, where blood glucose levels are unaffected [6] , thus, it is plausible that the other factors are primarily vascular in origin. These would include increased sympathetic tone and elevated 0~-adrenoceptor sensitivity [11] , increased vasoconstriction related to the renin-angiotensin system [9] , and changes in vascular smooth muscle Ca 2+ channel activity [12] , since blockers of all these actions improve nerve function in diabetic rats [3, 38, 41, [43] [44] [45] .
A further contribution to endoneurial hypoxia in diabetes could come from increased blood viscosity, impaired fibrinolysis, reduced erythrocyte deformability, and decreased oxygen unloading from haemoglobin [46, 47] . It is questionable whether the latter three parameters would be changed by flurbiprofen-NOARG treatment in non-diabetic rats; however, viscosity may be increased by platelet aggregation [33] . Thus, a wider range of rheological factors may exacerbate nerve abnormalities in diabetic rats, compared with rats in which endothelium dysfunction is pharmacologically induced.
The effect of chronic NO inhibition on regional blood flow has been examined in conscious rats [48] . Over 9 h, hind-limb flow was 36 % reduced by a dose of approximately 75 mg. kg -1. day -1 of NC-nitro-L-arginine methyl ester (which has a similar potency to NOARG). The hindlimb supply is responsible for sciatic nerve perfusion, therefore, it is likely that there was a similar magnitude of flow reduction in this study. In diabetic rats, sciatic endoneurial blood flow is 40 % reduced compared with nondiabetic rats [3, 49] . Thus, given their synergistic action, 25 mg. kg -1. day -~ NOARG plus flurbiprofen treatment might be expected to cause NCV deficits similar to those for diabetes if a major determinant was the reduction in perfusion, which is supported by the data in this investigation.
Chronic low-dose NOARG treatment produced an approximately two-fold greater impairment of the already compromised nerve function in diabetic rats than was apparent for the same dose in non-diabetic rats. Greater sensitivity to an inhibitor might be predicted if NO production or action was already diminished in diabetic rats, as has been suggested from in vitro and in vivo studies [9, 10, 50] . The data also fit in with expectations from investigations of acute NO inhibitor administration on hind-limb blood flow in conscious diabetic rats, which provide evidence of impaired basal and stimulated NO synthesis [19, 20] . This effect may have parallels in diabetic patients where deficits in NO production have been demonstrated [16] and neuropathy is exacerbated by vascular insufficiency [51] .
The data for capillary density showed that there was no significant effect of flurbiprofen or NOARG treatment in non-diabetic rats except for the two groups subjected to the highest degree of blockade, despite the likelihood of reduced vasa nervorum blood flow for all treatments [15, 19] . Several previous studies have also demonstrated that capillary density is not decreased by untreated diabetes [23, 38, 41, 44] , despite a 40% decline in blood flow [3] . However, in the low-dose NOARG-treated diabetic rats there was regression of the capillary bed. Experiments using several vasodilator treatments [23, 37, 38, 41, 45] re-vealed vasa nervorum angiogenesis in diabetic rats, whereas for treated non-diabetic rats angiogenesis was not found despite increases in capillary size and patency [37, 38, 52] . This difference was attributed either to increases in blood flow in diabetic rats of sufficient magnitude to be suprathreshold for mechanical stimulation of angiogenesis [53] , or to the presence of circulating proliferative factors [38] . Taken together with data for NOARG treatment, however, the evidence leads to the general conclusion that the endoneurial vascular bed in diabetic rats shows greater susceptibility to manipulations likely to produce further changes in blood flow in either direction than is the case for non-diabetic rats. The reason for this is elusive, but if the argument also applies to patients, the need to therapeutically target the preservation of endothelial integrity is further emphasized.
In conclusion, the data demonstrate that a chronic deficit in endothelial vasodilator synthesis is sufficient to cause neuropathy in rats. Furthermore, exacerbation of existing endothelial abnormalities by NO inhibition in diabetic rats worsens nerve function. Together this suggests that the endothelial deficits found in diabetic rats and patients could substantially contribute to neuropathy.
